Richard Stone, MD, obtained his medical degree from Harvard Medical School in 1981, and completed an internal medicine residency program at Brigham and Women’s Hospital. He further trained as a hematology-oncology fellow at Dana-Farber Cancer Institute (DFCI). Prof. Stone is currently the Director of the Adult Acute Leukemia Program at DFCI and acts as a board member of the Medical Oncology Board at the American Board of Internal Medicine. He is also a Professor of Medicine at Harvard Medical School in Boston.
Prof. Stone is actively involved in numerous clinical studies on acute leukemia and related malignancies, and is Vice Chair of the Leukemia Core Committee for the national cooperative trials group, Cancer and Leukemia Group B.
Speaking on AML, CLL, MDS and myeloproliferative disorders
Prof. Stone focuses his research on acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative disorders. His research group is centred around identifying new targeted therapeutics in acute leukemia and myelodysplastic syndromes. This includes targeting FLT3 tyrosine kinases in patients with AML. He also investigates mechanisms of NOTCH activation in T-cell ALL and other drug research targets including NEDD-8 inhibitors, HSP90 inhibitors and MEK inhibitors.